Reviewer Relationships With Industry and Other Entities (Comprehensive)—2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Joseph C. Cleveland, Jr.	Official Reviewer— ACC Board of Governors	University of Colorado Anschutz Medical Center—Fred and Carol Grover Chair of Surgery; Professor of Surgery; Vice- Chair, Faculty Affairs, Department of Surgery; Surgical Director, Cardiac Transplantation, Division of CT Surgery	None	None	None	• Abbott	• Abbott‡	None
Gregory J. Dehmer	Official Reviewer— Solution Set Oversight Committee (SSOC)	Virginia Tech Carilion School of Medicine; Carilion Clinic, Cardiology and Carilion Cardiovascular Institute— Medical Director, Quality and Outcomes	 American Board of Internal Medicine CMS MedCAC Panel FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee 	None	None	• SCAI*	None	None
Larry A. Allen	Content Reviewer— Individual Expert	University of Colorado, School of Medicine— Professor, Medicine; Associate Head, Clinical Affairs, Cardiology; Medical Director, Advanced Heart Failure	 ACI Clinical[†] Amgen Boston Scientific DCRI Janssen Scientific Affairs, Johnson and Johnson 	None	None	 AHA† NIH/NHLBI† PCORI† 	None	None
MaryBeth Brady	Content Reviewer— Roundtable Participant	Johns Hopkins University School of Medicine—Vice Chair for Education, Department of Anesthesiology and Critical	None	None	None	None	None	None

David A. Cox	Content Reviewer— SCAI	Care Medicine; Associate Professor, Anesthesiology and Critical Care Medicine Cardiovascular Associates—Director, Cardiac Cath Lab; Director, Cardiology QA/PI; Brookwood Baptist Health	 Abbott Vascular Biotronik Boston Scientific Medtronic 	None	None	None	Medtronic‡	• Defendant, Inappropria te PCI, 2018†
Jennifer L. Ellis	Content Reviewer— Roundtable Participant	Medstar Washington Hospital—Senior Cardiac Surgeon, Medstar Heart and Vascular Institute	None	None	None	None	None	None
Marci Farquhar- Snow	Content Reviewer— Cardiovascular Team Council	Mayo Clinic Arizona— Nurse Practitioner	None	None	None	None	None	None
Rebecca T. Hahn	Content Reviewer— Individual Expert	Columbia University College of Physicians and Surgeons—Associate Professor of Clinical Medicine	GoreNaviGatePhilips Healthcare	 Abbott Vascular Boston Scientific Siemens Healthineers 	None	None	Echo Core Lab*	None
Ashequl M. Islam	Content Reviewer— Roundtable Participant	Baystate Medical Center— Interventional Cardiologist; Tufts University School of Medicine—Clinical Associate Professor of Medicine	• Medtronic†	None	None	None	None	None
Samir R. Kapadia	Content Reviewer— Roundtable Participant	Cleveland Clinic Foundation—Chairman, Department of Cardiovascular Medicine; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University—Professor of Medicine	None	None	None	None	 Abbott Laboratories* Abbott Laboratories‡ Boston Scientific* Catheterization Laboratory Supplies at Cleveland Clinic* Claret Medical* Claret Medical‡ DFM‡ 	None

							 Edwards Lifesciences* Edwards Lifesciences‡ Navigate† St. Jude Medical* St. Jude Medical‡ 	
Clifford J. Kavinsky	Content Reviewer— SCAI	Rush University Medical Center—Professor of Medicine and Pediatrics; Director, Rush Center for Adult Structural Heart Disease; Director, Cardiovascular Fellowship Training Program	None	None	None	None	 Abbott Laboratories‡ Edwards Lifesciences‡ 	None
Vaikom S. Mahadevan	Content Reviewer— Roundtable Participant	University of California, San Francisco—Professor of Medicine; Director of Structural and Adult Congenital Cardiac Interventions; William W. Parmley Endowed Chair in Cardiology; Associate Chief of Interventional Cardiology	• Abbott	None	None	None	 Abbott Laboratories‡ Edwards Lifesciences Edwards Lifesciences‡ 	None
Daniel D. Matlock	Content Reviewer— Individual Expert	University of Colorado— Associate Professor, Medicine and Geriatrics	None	None	None	 ACC Foundation[†] Colorado Health Foundation[†] NIH[†] PCORI[†] 	None	None
Paul Sorajja	Content Reviewer— Individual Expert	Abbott Northwestern Hospital—Director, Center for Valve and Structural Heart Disease Minneapolis Heart Institute	 Abbott Vascular† Admedus Boston Scientific Edwards Lifesciences Gore Medtronic 	 Abbott Vascular† Edwards Lifesciences Medtronic 	None	None	None	None
Randall C. Starling	Content Reviewer— Roundtable Participant	Cleveland Clinic— Professor of Medicine; President Heart Failure	MedtronicNovartis	None	None	 Abbott* Cardiac Dimensions* 	 Amgen‡ Corvia Medical‡	None

		Society of America, Kaufman Center for Heart Failure, Heart and Vascular Institute				 Medtronic NIH[†] Novartis[*] 	• Novartis‡	
Molly Szerlip	Content Reviewer— SCAI	The Heart Group— Interventional Cardiologist	Edwards LifesciencesMedtronic	 Abiomed* Edwards Lifesciences* 	None	None	 Bayer‡ Edwards Lifesciences‡ Medtronic‡ 	None
Vinod H. Thourani	Content Reviewer— Roundtable Participant	Georgetown University School of Medicine— Professor of Surgery; Medstar Heart and Vascular Institute—Chair, Department of Cardiac Surgery	 Boston Scientific Edwards Lifesciences Gore Vascular JenaValve 	None	None	 Abbott Medical Medtronic* 	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of \geq 5% of the voting stock or share of the business entity, or ownership of \geq \$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <u>http://www.acc.org/guidelines/about-guidelines-and-clinicaldocuments/relationships-with-industry-policy</u> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

* No financial benefit.

† Significant relationship.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

ACC=American College of Cardiology; AHA=American Heart Association; CMS=The Centers for Medicare & Medicaid Services; CT=cardiothoracic; DAPT=dual antiplatelet therapy; DCRI=Duke Clinical Research Institute; FDA=Food and Drug Administration; MedCAC=Medicare Evidence Development & Coverage Advisory Committee; NHLBI= National Heart, Lung, and Blood Institute; NIH=National Institutes of Health; PCI=percutaneous coronary intervention; PCORI= Patient-Centered Outcomes Research Institute; QA/PI=quality assurance/performance improvement; SCAI=Society for Cardiac Angiography and Interventions.